TRX
NEUTRALTissue Regenix Concludes Strategic Review, Focuses on Standalone Growth
The regenerative medical devices company has concluded its strategic review without a sale, and will now focus on delivering growth as an independent business.
Tissue Regenix Group
31.00GBX
-1.59%
Market Cap
22.44M
Volume
25.23k
86% of avg
P/E Ratio
0.40
EPS (TTM)
0.77
Beta
0.93
Day Range
30.00p - 31.85p
52 Week Range
30.00p31.00p75.00p
31.00p
Upcoming Events
5 December 2024
Threshold for major shareholding change crossed
High Impact Event
TRX
NEUTRALTissue Regenix Granted European Patent for Decellularisation Technology
The medical technology company has been granted a European patent for its innovative decellularisation technology, further protecting its intellectual property.
TRX
NEUTRALTissue Regenix Provides Company Update
The medical technology company provides a general update on its business, indicating it continues to execute on its strategy as it looks to drive further growth in 2025.
TRX
GOODTissue Regenix Reports Continued Growth and Profitability in FY24 Trading Update
The regenerative medical devices company reported 8% revenue growth and expects to exceed profit expectations for the full year, marking a second consecutive year of profitability. However, the strategic review of a German joint venture introduces some uncertainty.
TRX
NEUTRALLexham Special Opportunities I LP Increases Stake in Tissue Regenix
Tissue Regenix, a medical technology company, sees a change in its shareholder structure.
TRX
NEUTRALTissue Regenix Sees Increase in Institutional Investor Holding
Medical technology company Tissue Regenix sees increase in institutional investor holding, but limited information provided on current performance.
TRX
BADMajor Shareholder Reduces Stake in Tissue Regenix Group
Biotech company sees major shareholder reduce stake
TRX
GOODTissue Regenix Extends Orthopaedic Distribution Deal with Arthrex
Regenerative medical device company extends distribution deal with leading orthopaedic solutions provider
TRX
NEUTRALDirector Increases Stake in Tissue Regenix Group
A small biotech company sees a director increase their stake, but the impact on the share price is unclear.
TRX
NEUTRALTissue Regenix Explores Strategic Options, Potential Sale
Medical device company explores options to maximize shareholder value